JNJ-77242113 Matching Placebo

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

17 competitors in Plaque Psoriasis

#DrugCompanyPhaseTrials

1

Stelara

Johnson & Johnson

Phase 3

22

Tremfya

Johnson & Johnson

Phase 3

13

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

34

JNJ-77242113

Johnson & Johnson

Phase 3

55

JNJ-77242113 Matching Placebo

Johnson & Johnson

Phase 3

26

ORKA-001

OOruka Therapeutics, Inc.

Phase 2

37

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Plaque Psoriasis2 trials

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Active, not recruiting·Johnson & Johnson·Phase 3·NCT06220604·731 enrolled

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Active, not recruiting·Johnson & Johnson·Phase 3·NCT06143878·774 enrolled

Details

Drug Info

Related News